Publication:
Successful infliximab treatment in siblings with netherton syndrome: unveiling a novel SPINK5 gene variant and literature review

Placeholder

School / College / Institute

Organizational Unit
Organizational Unit
Organizational Unit
Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Editor & Affiliation

Compiler & Affiliation

Translator

Other Contributor

Date

Language

Embargo Status

N/A

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Netherton syndrome (NS) is a rare autosomal recessive genodermatosis. In this article, we present two siblings with NS who harbour a novel variant in the SPINK5 gene and were treated with infliximab infusions. Both patients exhibited the characteristic clinical triad of NS, and their whole exome sequencing analysis revealed a homozygous variant, c.1820+53G>A, in the SPINK5 gene. Notably, this is the first documented instance of homozygosity for this particular variant. Despite the absence of a specific treatment, both patients achieved total clearance of the skin lesions, and a significant decrease in total IgE levels was documented.

Source

Publisher

Wiley

Subject

Dermatology

Citation

Has Part

Source

Australasian Journal of Dermatology

Book Series Title

Edition

DOI

10.1111/ajd.14234

item.page.datauri

Link

Rights

N/A

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

Related Goal

Thumbnail Image
GoalOpen Access
03 - Good Health and Well-being
Over the last 15 years, the number of childhood deaths has been cut in half. This proves that it is possible to win the fight against almost every disease. Still, we are spending an astonishing amount of money and resources on treating illnesses that are surprisingly easy to prevent. The new goal for worldwide Good Health promotes healthy lifestyles, preventive measures and modern, efficient healthcare for everyone.

0

Views

0

Downloads

View PlumX Details